Melatonin Studies of Totally Blind Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00795236 |
Recruitment Status :
Terminated
(Unique provision in the American Recovery and Reinvestment Act prevented approval of second year no-cost-extension in which completion of analyses were planned.)
First Posted : November 21, 2008
Results First Posted : November 27, 2019
Last Update Posted : November 27, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sleep Disorder Blindness | Drug: Melatonin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Melatonin Studies in Young Blind Children and Adolescents |
Study Start Date : | November 2009 |
Actual Primary Completion Date : | June 2015 |
Actual Study Completion Date : | June 2015 |

Arm | Intervention/treatment |
---|---|
No Intervention: Observational
Observe to determine free-running versus entrained status.
|
|
Experimental: Melatonin
Subjects with free-running rhythms will take melatonin.
|
Drug: Melatonin
One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study. |
- To Test for a Proportional Gender Difference in Circadian Status (Free-running Versus Entrained) in Blind Children and in Adolescents, a Chi-square Test of Significance Will be Used for Each Age Group. [ Time Frame: Approximately 1 year ]
- To Test for a Proportional Difference in Circadian Status (Free-running Versus Entrained) Between Pre and Post- Pubertal Males in Blind Boys and Young Men, a Chi-square Test of Significance Will be Used for Each Age Group. [ Time Frame: Approximately 1 year ]
- To Determine the Efficacy of Melatonin Treatment in Entraining Blind Free-running Children and Young Adults, a Binomial Test Will be Used. [ Time Frame: Approximately 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 20 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Totally blind
- Between 5-8 yrs or 17-20 yrs of age
Exclusion Criteria:
- Pregnancy
- Light perception
- Low melatonin production
- Taking melatonin
- Co-morbid medical disorders (such as seizure disorders)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00795236
United States, Oregon | |
Oregon Health and Science University | |
Portland, Oregon, United States, 97239 |
Principal Investigator: | Alfred Lewy, MD, PhD | Oregon Health and Science University |
Responsible Party: | Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00795236 History of Changes |
Other Study ID Numbers: |
eIRB 4664 2R01HD042125-06 ( U.S. NIH Grant/Contract ) |
First Posted: | November 21, 2008 Key Record Dates |
Results First Posted: | November 27, 2019 |
Last Update Posted: | November 27, 2019 |
Last Verified: | November 2019 |
melatonin |
Sleep Wake Disorders Blindness Nervous System Diseases Neurologic Manifestations Signs and Symptoms Mental Disorders Vision Disorders Sensation Disorders |
Eye Diseases Melatonin Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Central Nervous System Depressants |